Techniclone International Corp., Brilliance Shanghai Pharmaceuticals deal

TCLN and Brilliance (Shanghai) will develop TCLN's Tumor Necrosis Technologies (TNT) in China as a means of detecting solid tumor types.

Brilliance will fund $3 million of research on the product at the University of Southern California. TCLN (Tustin, Calif.) retains exclusive rights to the technology outside of China. ...